Ben Markman Selected Research

Ben Markman Research Topics

Disease

25	Neoplasms (Cancer) 03/2024 - 10/2008
5	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 11/2009
5	Disease Progression 01/2023 - 01/2020
2	Nausea 08/2020 - 01/2018
2	Melanoma (Melanoma, Malignant) 01/2020 - 05/2012
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 12/2018
2	Lung Neoplasms (Lung Cancer) 05/2012 - 08/2010
1	Hepatitis 12/2021
1	Adrenocortical Carcinoma 12/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Vomiting 08/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2020
1	Papillary Thyroid Cancer 01/2020
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2020
1	Carcinoid Tumor (Carcinoid) 01/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2020
1	Colitis 01/2020
1	Pneumonia (Pneumonitis) 01/2020
1	Thyroid Neoplasms (Thyroid Cancer) 01/2020
1	Endometrial Neoplasms (Endometrial Cancer) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 12/2018
1	Triple Negative Breast Neoplasms 12/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Dehydration (Water Stress) 01/2018
1	Anorexia 01/2018
1	Abdominal Pain (Pain, Abdominal) 01/2018
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2018
1	Fatigue 01/2018
1	Heart Failure 01/2018
1	Pulmonary Hypertension 01/2018
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 11/2009
1	Breast Neoplasms (Breast Cancer) 10/2008

Drug/Important Bio-Agent (IBA)

5	NivolumabIBA 01/2022 - 01/2020
5	IpilimumabIBA 12/2021 - 05/2012
4	ErbB Receptors (EGF Receptor)IBA 10/2011 - 11/2009
3	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2020
3	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2020
3	Panitumumab (Vectibix)FDA Link 05/2012 - 11/2009
3	Trastuzumab (Herceptin)FDA Link 05/2012 - 10/2008
3	Cetuximab (Erbitux)FDA Link 05/2012 - 11/2009
2	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2021
2	Programmed Cell Death 1 ReceptorIBA 03/2024 - 11/2021
2	Mechanistic Target of Rapamycin Complex 1IBA 05/2014 - 05/2011
2	Bevacizumab (Avastin)FDA Link 05/2012 - 08/2010
2	catumaxomabIBA 05/2012 - 08/2010
2	Monoclonal AntibodiesIBA 05/2012 - 10/2011
1	regorafenibIBA 11/2023
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2023
1	Gefitinib (Iressa)FDA Link 01/2023
1	VemurafenibIBA 01/2023
1	durvalumabIBA 01/2023
1	AntibodiesIBA 01/2023
1	MesothelinIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	B7-H1 AntigenIBA 11/2021
1	Docetaxel (Taxotere)FDA Link 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 08/2020
1	tislelizumabIBA 01/2020
1	Adenosine (Adenocard)FDA LinkGeneric 01/2020
1	Codon (Codons)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	N- (4- ((3- (2- amino- 4- pyrimidinyl)- 2- pyridinyl)oxy)phenyl)- 4- (4- methyl- 2- thienyl)- 1- phthalazinamineIBA 12/2018
1	PlatinumIBA 12/2018
1	taxaneIBA 12/2018
1	Cisplatin (Platino)FDA LinkGeneric 12/2018
1	Etoposide (VP 16)FDA LinkGeneric 12/2018
1	Aurora KinasesIBA 12/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2018
1	LigandsIBA 01/2018
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2018
1	Pemetrexed (MTA)FDA Link 01/2018
1	Carboplatin (JM8)FDA LinkGeneric 01/2018
1	demcizumabIBA 01/2018
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018
1	napabucasinIBA 01/2018
1	Hyaluronic Acid (Hyaluronan)IBA 01/2018
1	Mechanistic Target of Rapamycin Complex 2IBA 05/2014
1	XL765IBA 05/2014
1	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2014
1	Drug CombinationsIBA 01/2013
1	Denosumab FDA Link 05/2012
1	Cytotoxins (Cytolysins)IBA 05/2012
1	imgatuzumabIBA 10/2011
1	MTOR InhibitorsIBA 11/2010
1	dactolisibIBA 10/2008
1	Ribosomal Proteins (Ribosomal Protein)IBA 10/2008
1	Everolimus FDA Link 10/2008
1	TensinsIBA 10/2008
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2008

Therapy/Procedure

15	Therapeutics 03/2024 - 10/2008
7	Immunotherapy 12/2021 - 01/2016
5	Drug Therapy (Chemotherapy) 08/2020 - 01/2018
1	Chemoradiotherapy 01/2023
1	Radiotherapy 01/2021
1	Castration 12/2018